Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Issue 6 (11th May 2020)

• Record Type: Journal Article
• Authors: Roussel, Murielle; Hebraud, Benjamin; Hulin, Cyrille; Perrot, Aurore; Caillot, Denis; Stoppa, Anne-Marie; Macro, Margaret; Escoffre, Martine; Arnulf, Bertrand; Belhadj, Karim; Karlin, Lionel; Garderet, Laurent; Facon, Thierry; Guo, Shien; Weng, Josh; Dhanasiri, Sujith; Leleu, Xavier; Moreau, Philippe; Attal, Michel
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 6(2020)
• Page Start: 1323
• Page End: 1333
• Publication Date: 2020-05-11
• Subjects: Quality of life -- multiple myeloma -- autologous stem cell transplantation -- lenalidomide -- bortezomib -- dexamethasone; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1719091
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The Intergroupe Francophone du Myelome 2009 trial (NCT01191060) assessed health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide/bortezomib/dexamethasone (RVd) induction therapy followed by consolidation therapy with either autologous stem cell transplantation (ASCT) plus RVd (RVd-ASCT) or RVd-alone; both groups then received lenalidomide maintenance therapy for 1 year. Global HRQoL, physical functioning, and role functioning scores significantly improved for both cohorts from baseline to the end of consolidation and were sustained during maintenance and follow-up, with clinically meaningful changes (RVd-alone: p = .0002; RVd-ASCT: p < .001). Similarly, both groups showed clinically meaningful improvements from baseline in fatigue, pain, and disease symptom scores. Side effects of treatment scores remained stable. In the RVd-ASCT group, there was transient worsening in HRQoL immediately after ASCT. These findings suggest that the clinical improvements observed with RVd-based treatment are accompanied by overall improvements in HRQoL for patients with NDMM.